查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924708

猴痘抗體檢測試劑市場按檢測類型、技術平台、檢體類型、最終用戶、應用和銷售管道分類－2026-2032年全球預測

Monkeypox Antibody Test Reagent Market by Test Type, Technology Platform, Sample Type, End User, Application, Sales Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，猴痘抗體檢測試劑市場價值將達到 1.5353 億美元，到 2026 年將成長至 1.7434 億美元，到 2032 年將達到 3.3513 億美元，複合年成長率為 11.79%。

關鍵市場統計數據
基準年 2025 1.5353億美元
預計年份：2026年 1.7434億美元
預測年份 2032 3.3513億美元
複合年成長率 (%) 11.79%

一份全面的執行簡報，重點闡述了猴痘抗體檢測試劑對臨床、監測和調查相關人員的策略重要性。

本執行摘要為診斷、臨床護理、公共衛生和研究機構的領導者提供關於猴痘抗體檢測試劑的策略指南，這些試劑是為猴痘檢測和監測而開發的。隨著臨床需求的恢復、監測優先順序的提高以及對檢測特異性和安全性的日益重視，市場格局正在迅速變化。從檢測設計到分銷，對試劑開發過程的分析重點闡述了影響其在不同環境中應用的技術和商業性因素。

變革性變化正在推動跨平台、抗體標靶、監測重點和照護現場擴展的檢測開發和部署。

猴痘抗體試劑領域正經歷著變革性的轉變，這重塑了研發、檢驗和部署的優先事項。技術革新是其核心。化學和檢測方法的進步正在縮小實驗室級檢測與快速現場部署解決方案之間的差距。改進的抗原設計和增強的訊號放大提高了痘病毒抗體陽性檢測的特異性，而樣本處理的改進則降低了分析前變異性。因此，相關人員越來越能夠權衡通量、靈敏度和操作簡便性之間的利弊。

評估美國於2025年宣布的關稅對試劑採購、生產經濟和分銷網路的累積影響

美國2025年前後的關稅政策趨勢為猴痘抗體檢測試劑採購領域的相關人員帶來了新的挑戰。對進口原料、成品試劑和輔助組件徵收的關稅措施可能會改變生產商和採購商的經濟考量，影響他們是否選擇將生產遷回國內或繼續依賴現有國際供應商。在此背景下，各組織必須重新評估籌資策略，以確保供應的連續性，同時控制單位成本並履行合約義務。

從詳細的細分觀點揭示測試類型、平台、檢體基質、產品形式、應用、最終用戶和銷售管道如何影響試劑需求。

對市場區隔進行細緻分析，可以揭示技術和商業性決策如何影響試劑性能和市場定位。根據檢測類型，檢測 IgA、IgG、IgM 和總抗體的檢測方法需要不同的抗原呈現和檢驗策略，以確保特異性和有意義的臨床解釋。急性感染檢測與先前感染檢測的性能特徵取決於這些抗體標靶的選擇和最佳化。

影響美洲、歐洲、中東和非洲以及亞太市場試劑採用和供應鏈韌性的區域趨勢

區域趨勢對試劑供應、監管預期和實施路徑有顯著影響。在美洲，許多公共衛生機構和大型醫院系統優先考慮與實驗室資訊系統快速整合，尋求明確的性能證據，並評估能夠支持臨床診斷和大規模血清流行病學調查的多方相關人員採購模式。因此，在該地區運營的製造商和經銷商通常會優先考慮合規性、強大的客戶支援和可擴展的物流解決方案。

競爭考察聚焦於創新藍圖、生產規模、監管策略、夥伴關係模式和差異化的商業性策略。

競爭考察揭示了決定抗體試劑領域成功與否的幾個通用策略主題。首先，優先考慮高特異性抗原、簡化工作流程以及與多種檢體基質相容性的創新藍圖，能夠為在不同環境下運作的客戶創造永續價值。其次，生產規模和垂直整合決定了企業滿足需求高峰和提供理想前置作業時間的能力，因此與契約製造工廠合作是擴大產能的常用途徑。

為最佳化研發重點、增強供應鏈韌性以及加速臨床和公共衛生領域的應用，提供實際的策略建議。

產業領導者應採取切實可行的優先行動方案，以鞏固市場地位並支持公共衛生目標。首先，投資於跨平台相容性將使CLIA認證系統、ELISA平台和側向層析檢驗試劑能夠以模組化解決方案的形式交付，從而滿足不同終端用戶的需求。這種柔軟性將減輕買方負擔，並支援在中心檢查室和分散式環境中同時部署。

一套嚴謹的調查方法，闡述了初級和次級資料收集、檢測檢驗、相關人員訪談以及三角測量技術。

本執行摘要的調查方法結合了多種資料收集和檢驗技術，以確保其相關性和嚴謹性。關鍵資料來源包括對實驗室主任、醫院採購人員、公共衛生專案經理和檢測方法開發人員進行結構化訪談，以了解營運限制、採購慣例和績效預期。這些訪談旨在識別實施過程中的實際障礙，並挖掘臨床診斷、流行病學監測、研究和疫苗開發等領域的真實應用案例。

簡要結論總結了主要發現、對相關人員的策略意義以及試劑創新和部署的未來優先事項。

本概要總結了影響猴痘抗體試劑生態系統的關鍵促進因素，並概述了對製造商、經銷商和機構採購者的戰略意義。 CLIA、ELISA 和側向層析平台的技術進步正在拓展實際應用環境的範圍，而監管機構持續強調嚴格的檢驗，確保檢測能夠滿足臨床和流行病學需求。受關稅政策影響的生產規模、分銷網路和供應鏈韌性仍然是保障供應和控制成本的關鍵因素。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：猴痘抗體檢測試劑市場（依檢測類型分類）

  • IgA
  • IgG
  • IgM

9. 依技術平台分類的猴痘抗體檢測試劑市場

  • CLIA
  • ELISA
  • 快速交叉流法
    • 膠體金
    • 螢光法

第10章：依檢體類型分類的猴痘抗體檢測試劑市場

  • 電漿
  • 血清
  • 全血

第11章 猴痘抗體檢測試劑市場（依最終用戶分類）

  • 診斷檢查室
  • 醫院
  • 公共衛生檢查室
  • 研究所

第12章：猴痘抗體檢測試劑市場（依應用領域分類）

  • 臨床診斷
  • 流行病學監測
  • 研究
  • 疫苗研發

第13章 猴痘抗體檢測試劑市場（依銷售管道分類）

  • 離線
  • 線上

第14章 猴痘抗體檢測試劑市場（依地區分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 猴痘抗體檢測試劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國猴痘抗體檢測試劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國猴痘抗體檢測試劑市場

第18章：中國猴痘抗體檢測試劑市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AdvaCare Pharma Pvt. Ltd.
  • Applied DNA Clinical Labs, Inc.
  • Becton, Dickinson and Company
  • CerTest Biotec SL
  • FineTest International Co., Ltd.
  • Hangzhou AllTest Biotech Co., Ltd.
  • JOYSBIO Biotechnology Co., Ltd.
  • Laboratory Corporation of America Holdings
  • Mylab Discovery Solutions Pvt. Ltd.
  • Quest Diagnostics Incorporated
  • RayBiotech, Inc.
  • Roche Diagnostics GmbH
  • Sansure Biotech Inc.
  • Siemens Healthineers AG
  • Sino Biological Inc.
  • Vitrosens Diagnostics Pvt. Ltd.
Product Code: MRR-7A380DA7C43F

The Monkeypox Antibody Test Reagent Market was valued at USD 153.53 million in 2025 and is projected to grow to USD 174.34 million in 2026, with a CAGR of 11.79%, reaching USD 335.13 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 153.53 million
Estimated Year [2026] USD 174.34 million
Forecast Year [2032] USD 335.13 million
CAGR (%) 11.79%

Comprehensive executive overview highlighting the strategic importance of monkeypox antibody test reagents for clinical, surveillance, and research stakeholders

This executive summary provides a strategic orientation to antibody test reagents developed for monkeypox detection and surveillance, intended for leaders across diagnostics, clinical care, public health, and research organizations. The landscape has evolved rapidly, driven by renewed clinical demand, heightened surveillance priorities, and an intensified focus on assay specificity and safety. Examining reagent development from assay design through distribution reveals both technical and commercial levers that influence adoption across diverse settings.

The purpose of this document is to synthesize the most relevant developments and to clarify decision points for stakeholders who must balance clinical performance with operational feasibility. It highlights the interplay between assay biology, platform selection, sample handling, and end-user requirements, and it underscores the importance of aligning product formats with procurement channels and regulatory expectations. Furthermore, the summary emphasizes how diagnostic needs differ between centralized laboratories and point-of-care environments, and why those differences matter for reagent formulation and packaging.

Readers will find concise analyses of shifting dynamics, segmentation-driven implications, regional considerations, and concrete actions that manufacturers, distributors, and institutional buyers can take. Throughout the summary, attention is given to the practical constraints and opportunities that shape reagent availability, assay reliability, and the integration of antibody testing into clinical and public-health workflows.

Transformational changes driving assay development and deployment across platforms, antibody targets, surveillance priorities, and point of care expansion

The landscape for monkeypox antibody reagents is experiencing transformative shifts that are reshaping priorities across development, validation, and deployment. Technological evolution is central: advances in chemistries and detection modalities are narrowing the gap between laboratory-grade assays and rapid, field-deployable solutions. Improved antigen design and enhanced signal amplification have bolstered assay specificity for orthopoxvirus antibodies, and concurrent refinements in sample processing have reduced pre-analytical variability. As a result, stakeholders are increasingly able to weigh trade-offs between throughput, sensitivity, and operational simplicity.

Regulatory and reimbursement pathways are adapting in parallel, with agencies emphasizing robust validation datasets and post-market surveillance to ensure performance in diverse populations. This regulatory emphasis is prompting manufacturers to invest earlier in multicenter validation and to design assays that accommodate different sample types and workflows. At the same time, the public-health imperative for seroprevalence and contact-tracing studies is accelerating demand for scalable formats that can be deployed in both clinical laboratories and community settings.

Market dynamics are also influenced by supply chain considerations and the need for manufacturing redundancy. Strategic partnerships between assay developers, contract manufacturers, and distribution networks are becoming more common as a way to de-risk supply while enabling rapid scale-up when needed. Finally, integration with digital reporting platforms and laboratory information systems is emerging as a differentiator that enhances epidemiological utility and accelerates clinical adoption. Taken together, these shifts are driving a more integrated, resilient, and performance-focused reagent ecosystem.

Evaluating the cumulative implications of United States tariff actions announced for 2025 on reagent sourcing, manufacturing economics, and distribution networks

Recent tariff developments in the United States for 2025 have introduced a new layer of complexity for stakeholders involved in sourcing monkeypox antibody test reagents. Tariff measures that apply to imported raw materials, finished reagents, and ancillary components alter the economic calculus for manufacturers and buyers, and they can influence decisions about onshoring production versus continuing to rely on established international suppliers. In this environment, organizations must reassess procurement strategies to ensure continuity of supply while managing unit costs and contractual obligations.

Tariffs tend to have asymmetric effects across product formats: bulk reagents that are shipped in large volumes and rely on high-throughput production inputs can experience significant cost pressure, whereas compact kit formats intended for point-of-care use are often subject to different tariff classifications and logistical considerations. Consequently, some manufacturers may shift to localized fill-and-finish operations or seek tariff-exempt pathways, while distributors and end users reassess vendor contracts and consider alternative sourcing arrangements. Such adjustments can affect lead times, packing configurations, and minimum order quantities.

From a downstream perspective, public-health laboratories and hospital systems that rely on predictable reagent supply for surveillance and routine testing must incorporate tariff-induced variability into inventory planning and contracting. At the same time, novel procurement strategies-such as multi-year supply agreements, diversified distributor networks, and collaborative purchasing consortia-are practical responses that can mitigate disruption. Ultimately, effective management of tariff impacts requires proactive cross-functional coordination among regulatory, procurement, and supply chain teams to preserve assay performance and accessibility.

Granular segmentation perspectives revealing how test types, platforms, sample matrices, product formats, applications, end users, and sales channels shape reagent demand

A nuanced view of segmentation reveals how technical and commercial decisions influence reagent performance and market positioning. Based on test type, distinctions among IgA, IgG, IgM, and assays that measure total antibody require different antigen presentations and validation strategies to ensure specificity and meaningful clinical interpretation. Performance characteristics for acute infection detection versus historical exposure rely on the selection and optimization of these antibody targets.

Based on technology platform, each analytical approach brings distinct advantages and constraints: CLIA-grade platforms deliver high-throughput, centralized diagnostics suitable for laboratory workflows; ELISA formats provide quantitative readouts that support epidemiological surveys and research applications; and rapid lateral flow assays offer the speed and simplicity needed for point-of-care screening, with subvariants such as colloidal gold and fluorescent readers creating further performance and cost trade-offs. Based on end user, diagnostic laboratories and hospitals prioritize batch processing and traceability, public health laboratories require scalability for surveillance and contact tracing, and research institutes often demand flexibility for exploratory studies.

Based on sample type, reagent chemistry must be compatible with plasma, serum, or whole blood matrices, as pre-analytical conditions vary across collection settings. Based on product format, choices between bulk reagent and finished kits affect storage, distribution, and on-site handling. Based on application, differentiation among clinical diagnosis, epidemiological surveillance, research, and vaccine development informs performance targets, with clinical diagnosis subdivided into central lab and point of care, and epidemiological surveillance subdivided into contact tracing studies and seroprevalence surveys. Finally, based on sales channel, strategies range from direct sales-via government and private contracts-to distribution models with national or regional partners and online sales channels, each shaping commercial cadence and customer support expectations.

Regional dynamics shaping reagent adoption and supply chain resilience across the Americas, Europe Middle East & Africa, and Asia Pacific markets

Regional dynamics exert a strong influence on reagent availability, regulatory expectations, and adoption pathways. In the Americas, many public-health agencies and large hospital systems emphasize rapid integration with laboratory information systems, demand clear performance evidence, and value multi-stakeholder procurement approaches that can support both clinical diagnosis and large-scale seroprevalence studies. Consequently, manufacturers and distributors operating in this region often prioritize regulatory alignment, robust customer support, and scalable logistics solutions.

In Europe, Middle East & Africa, regulatory fragmentation and diverse infrastructure profiles require adaptable product strategies and flexible distribution models. Several countries prioritize centralized laboratory networks while others need point-of-care solutions for remote settings; therefore, suppliers must offer a portfolio that spans CLIA-equivalent platforms, ELISA kits, and robust lateral flow devices. Additionally, capacity building and technical transfer initiatives often accompany reagent deployment to ensure sustainable use.

In Asia-Pacific, the combination of advanced manufacturing capacity and significant public-health program activity creates both competition and collaboration opportunities. High-volume procurement programs, regional manufacturing hubs, and well-established contract manufacturing organizations support rapid scale-up, whereas heterogeneity in regulatory pathways and varying clinical practices mean that tailored validation packages and localized technical support are essential. Across all regions, resilience in the supply chain, clarity on customs and import requirements, and rapid response capabilities are decisive factors affecting adoption.

Competitive company insights focused on innovation roadmaps, manufacturing scale, regulatory strategies, partnership models, and differentiated commercial approaches

Competitive company insights point to several recurring strategic themes that influence who succeeds in the antibody reagent segment. First, innovation roadmaps that prioritize high-specificity antigens, simplified workflows, and compatibility with multiple sample matrices create enduring value for customers who must operate across diverse settings. Second, manufacturing scale and vertical integration often determine the ability to meet surge demand and to offer favorable lead times, making partnerships with contract manufacturers a common avenue for capacity expansion.

Regulatory strategy is another differentiator: companies that invest early in harmonized validation studies and maintain clear documentation for cross-border regulatory submissions reduce time-to-adoption and lower friction in procurement processes. Partnership models-whether through co-development with academic centers, distribution agreements with regional players, or collaborations with digital-health vendors-extend market reach and can accelerate integration into clinical and public-health workflows.

Commercial approaches that combine direct contracting with government agencies, targeted distributor relationships, and selective online offerings enable firms to balance scale with localized service. Leaders also emphasize post-market surveillance, customer training, and technical support as mechanisms to preserve product reputation and to gather real-world performance data that can inform iterative improvements. In sum, companies that align innovation, scale, regulatory foresight, and channel strategy are best positioned to capture long-term relevance in the reagent space.

Actionable strategic recommendations to optimize research and development focus, strengthen supply chain resilience, and speed clinical and public health adoption

Industry leaders should pursue a set of pragmatic, prioritized actions to strengthen market position and to support public-health goals. First, invest in cross-platform compatibility so that reagents validated on CLIA-grade systems, ELISA platforms, and lateral flow formats can be offered as modular solutions that meet diverse end-user needs. Such flexibility reduces friction for buyers and supports simultaneous deployment in central labs and decentralized settings.

Second, accelerate partnerships that expand manufacturing redundancy and local fill-and-finish capabilities to mitigate tariff and logistics risk. Complementary measures include establishing multi-year contracting arrangements with key buyers and implementing inventory strategies that account for lead-time variability. Third, prioritize validation studies that reflect real-world sample types-plasma, serum, and whole blood-and clearly document performance for both acute diagnosis and serological surveillance use cases.

Fourth, tailor commercial engagement to the sales channel: bespoke support models for government contracts, tiered service offerings for national and regional distributors, and streamlined online procurement for smaller institutions. Fifth, integrate digital reporting and quality-control solutions to enhance epidemiological value and customer trust. Finally, embed post-market surveillance and customer feedback loops into product lifecycles to enable rapid iteration and to address emerging variant or cross-reactivity concerns. Together, these steps will help organizations balance innovation, reliability, and responsiveness.

Robust research methodology explaining primary and secondary data collection, assay validation checks, stakeholder interviews, and triangulation methods

The research methodology underpinning this executive summary combines multiple data collection and validation techniques to ensure relevance and rigor. Primary inputs included structured interviews with laboratory directors, hospital procurement leads, public-health program managers, and assay developers to capture operational constraints, procurement practices, and performance expectations. These interviews were designed to identify practical barriers to adoption and to surface real-world use cases across clinical diagnosis, epidemiological surveillance, research, and vaccine development.

Secondary research involved a systematic review of technical literature, regulatory guidance, laboratory standards, and publicly available validation reports to contextualize assay performance claims and to understand cross-reactivity and matrix effects. Where possible, assay validation approaches were compared against established performance frameworks to evaluate claims around sensitivity, specificity, and reproducibility. Data triangulation was applied to reconcile differing accounts and to highlight robust patterns that emerged across sources.

Analytical steps included mapping segmentation dimensions against end-user requirements, assessing supply chain vulnerabilities, and synthesizing company strategies. Limitations of the methodology are acknowledged; for example, proprietary performance data and commercially confidential procurement terms are not publicly accessible. Nevertheless, the combination of stakeholder interviews, technical review, and cross-checking produced a coherent set of insights tailored to operational decision-makers.

Concise conclusion synthesizing key findings, strategic implications for stakeholders, and the forward-looking priorities for reagent innovation and deployment

This summary synthesizes the key drivers shaping the monkeypox antibody reagent ecosystem and outlines strategic implications for manufacturers, distributors, and institutional buyers. Technological progress across CLIA, ELISA, and lateral flow platforms is expanding the range of viable deployment settings, while ongoing regulatory emphasis on rigorous validation ensures assays meet clinical and epidemiological needs. Supply chain resiliency, influenced by manufacturing scale, distributor networks, and tariff dynamics, remains a practical determinant of availability and cost management.

Segmentation matters: differences in test type, platform, sample matrix, and product format create distinct value propositions that must be matched to end-user workflows and procurement channels. Regional constraints and opportunities further modulate adoption, with each geography requiring tailored validation, distribution, and support strategies. Companies that align innovation roadmaps with robust manufacturing and regulatory planning, and that leverage targeted commercial channels, will be best positioned to support both immediate clinical demands and long-term surveillance objectives.

In closing, the path forward requires coordinated efforts across R&D, manufacturing, and commercial teams, combined with proactive engagement with public-health stakeholders. By adopting flexible product portfolios, strengthening supply chain redundancy, and emphasizing real-world performance evidence, organizations can ensure that antibody testing contributes meaningfully to clinical care and population health goals.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Monkeypox Antibody Test Reagent Market, by Test Type

  • 8.1. Iga
  • 8.2. Igg
  • 8.3. Igm

9. Monkeypox Antibody Test Reagent Market, by Technology Platform

  • 9.1. Clia
  • 9.2. Elisa
  • 9.3. Rapid Lateral Flow
    • 9.3.1. Colloidal Gold
    • 9.3.2. Fluorescent

10. Monkeypox Antibody Test Reagent Market, by Sample Type

  • 10.1. Plasma
  • 10.2. Serum
  • 10.3. Whole Blood

11. Monkeypox Antibody Test Reagent Market, by End User

  • 11.1. Diagnostic Laboratory
  • 11.2. Hospital
  • 11.3. Public Health Laboratory
  • 11.4. Research Institute

12. Monkeypox Antibody Test Reagent Market, by Application

  • 12.1. Clinical Diagnosis
  • 12.2. Epidemiological Surveillance
  • 12.3. Research
  • 12.4. Vaccine Development

13. Monkeypox Antibody Test Reagent Market, by Sales Channel

  • 13.1. Offline
  • 13.2. Online

14. Monkeypox Antibody Test Reagent Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Monkeypox Antibody Test Reagent Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Monkeypox Antibody Test Reagent Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Monkeypox Antibody Test Reagent Market

18. China Monkeypox Antibody Test Reagent Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AdvaCare Pharma Pvt. Ltd.
  • 19.6. Applied DNA Clinical Labs, Inc.
  • 19.7. Becton, Dickinson and Company
  • 19.8. CerTest Biotec S.L.
  • 19.9. FineTest International Co., Ltd.
  • 19.10. Hangzhou AllTest Biotech Co., Ltd.
  • 19.11. JOYSBIO Biotechnology Co., Ltd.
  • 19.12. Laboratory Corporation of America Holdings
  • 19.13. Mylab Discovery Solutions Pvt. Ltd.
  • 19.14. Quest Diagnostics Incorporated
  • 19.15. RayBiotech, Inc.
  • 19.16. Roche Diagnostics GmbH
  • 19.17. Sansure Biotech Inc.
  • 19.18. Siemens Healthineers AG
  • 19.19. Sino Biological Inc.
  • 19.20. Vitrosens Diagnostics Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY IGM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY FLUORESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY FLUORESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY FLUORESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PUBLIC HEALTH LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PUBLIC HEALTH LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY PUBLIC HEALTH LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLINICAL DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY CLINICAL DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 149. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 150. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 173. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 174. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 181. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 182. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY RAPID LATERAL FLOW, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA MONKEYPOX ANTIBODY TEST REAGENT MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)